Skip to main content

Table 2 Hb responder analysis

From: Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data

      Number of    Percent with   
Outcome Comparator    Trials    Patients Ferric
carboxymaltose
   Control RB
95% CI
NNT
95% CI
Target Hb increase All    6    1715    78    63    1.2 (1.2 to 1.3)    6.8 (5.3 to 9.7)
  Oral iron    5    1481    74    59    1.3 (1.2 to 1.4)    6.6 (5.0 to 9.6)
Achieve target Hb level Oral iron    5    1509    79    62    1.3 (1.2 to 1.4)    5.9 (4.7 to 8.1)
Clinical success All    4    1167    70    2    37 (20 to 67)    1.5 (1.4 to 1.6)
  Oral iron    3    984    78    0    250 (51 to 1190)    1.3 (1.2 to 1.3)